Oxford BioMedica
Discover Realise

Products


______

Priority programmes (to be spun out or out-licensed)

OXB-102

A gene-based treatment for Parkinson's disease.

Read in full

OXB-202

A gene-based treatment for the prevention of corneal graft rejection.

Read in full

OXB-302

Read in full


______

Other candidates (to be spun out or out-licensed)

OXB-201

"Wet" age-related macular degeneration

Read in full

OXB-301

A therapeutic vaccine that stimulates the immune system to destroy cancerous cells expressing the 5T4 tumour antigen.

Read in full


______

Oxford BioMedica partnered products (development milestones and royalties)

SAR 422459

A gene-based therapy for the treatment of Stargardt disease.

Read in full

SAR 421869

A gene-based therapy for the treatment of Usher syndrome type 1B.

Read in full


______

IP enabled and royalty bearing products (process development and bioprocessing revenues, and royalties)

CTL-019

New opportunities

Read in full

Undisclosed CAR-T

Read in full

LV305

Read in full

Undisclosed

Read in full

Undisclosed

Read in full